May 27, 2021
May 27, 2021 –
The U.S. FDA has approved an expanded indication for Yervoy (ipilimumab), manufactured
by Bristol Myers Squibb, to be used in combination with nivolumab to treat
May 27, 2021
May 27, 2021 –
The U.S. FDA has approved a new indication for Zeposia® (ozanimod), manufactured by
Bristol Myers Squibb, to treat adults who have moderately to severely
May 27, 2021
May 27, 2021 –
The U.S. FDA has approved a new indication for Nurtec® ODT (rimegepant), manufactured
by Biohaven, for the preventive treatment of episodic migraines
May 26, 2021
May 26, 2021 –
The U.S. FDA has granted emergency use authorization (EUA) to GlaxoSmithKline’s
May 26, 2021
May 26, 2021 –
The U.S. FDA has issued a safety communication regarding the use of Ocaliva® (obeticholic
acid), manufactured by Intercept Pharmaceuticals, in certain patients who have
May 26, 2021
May 26, 2021 –
The U.S. FDA has approved Myfembree® (relugolix 40mg/estradiol 1mg/norethindrone
acetate 0.5mg), manufactured by Myovant and Pfizer
May 26, 2021
May 26, 2021 –
The U.S. FDA has approved Camcevi® (leuprolide mesylate), manufactured by Foresee
Pharmaceuticals, to treat advanced prostate cancer in adults.
May 21, 2021
May 21, 2021 –
The U.S. FDA has granted accelerated approval for RybrevantTM (amivantamab-vmjw),
manufactured by Janssen, to treat adults who have locally advanced